State Street Corp Raises Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

State Street Corp lifted its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 13.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,641,859 shares of the company's stock after acquiring an additional 440,890 shares during the period. State Street Corp owned approximately 3.58% of Dyne Therapeutics worth $130,816,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of DYN. FMR LLC increased its stake in Dyne Therapeutics by 69.7% in the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company's stock valued at $324,239,000 after buying an additional 3,707,734 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Dyne Therapeutics by 47.3% in the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company's stock valued at $244,755,000 after acquiring an additional 2,189,339 shares during the last quarter. RTW Investments LP raised its holdings in Dyne Therapeutics by 6.8% during the third quarter. RTW Investments LP now owns 6,818,641 shares of the company's stock worth $244,926,000 after acquiring an additional 431,503 shares in the last quarter. RA Capital Management L.P. boosted its position in Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company's stock valued at $229,211,000 after purchasing an additional 331,940 shares during the last quarter. Finally, First Light Asset Management LLC grew its stake in Dyne Therapeutics by 261.0% in the second quarter. First Light Asset Management LLC now owns 382,433 shares of the company's stock valued at $13,496,000 after purchasing an additional 276,485 shares in the last quarter. Institutional investors own 96.68% of the company's stock.

Insider Buying and Selling

In other news, COO Susanna Gatti High sold 8,976 shares of the company's stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the sale, the chief operating officer now directly owns 131,636 shares in the company, valued at $4,529,594.76. This represents a 6.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jason P. Rhodes sold 782 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total value of $25,884.20. Following the completion of the sale, the director now owns 15,962 shares in the company, valued at $528,342.20. This trade represents a 4.67 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 180,046 shares of company stock valued at $6,300,265. 20.77% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

DYN has been the topic of several analyst reports. Chardan Capital reaffirmed a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Royal Bank of Canada began coverage on shares of Dyne Therapeutics in a research note on Tuesday, November 26th. They issued an "outperform" rating and a $45.00 target price for the company. Robert W. Baird assumed coverage on Dyne Therapeutics in a research report on Friday. They set an "outperform" rating and a $46.00 price target on the stock. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an "overweight" rating to a "neutral" rating and reduced their target price for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. Finally, StockNews.com cut Dyne Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, September 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $50.42.

Dyne Therapeutics Trading Up 0.5 %

Shares of DYN traded up $0.12 on Friday, reaching $25.73. 840,351 shares of the company's stock traded hands, compared to its average volume of 1,445,920. The stock's 50 day simple moving average is $30.39 and its two-hundred day simple moving average is $35.23. Dyne Therapeutics, Inc. has a 52-week low of $11.51 and a 52-week high of $47.45. The stock has a market cap of $2.62 billion, a PE ratio of -7.23 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). Analysts forecast that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.